Nature Biotechnology ’ s academic spinouts of 2014

  • Bouchie A
  • Defrancesco L
  • 42


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Ventures focusing on drug testing or therapies against rare disease, cancer, gastrointestinal disease, fibrosis and pain are among those selected by the editors in 2014’s crop of startups. I n 2014, the biotech sector posted the largest ever influx of private funding since Nature Biotechnology was founded—a total of $9 bil- lion, up 50% from the previous year. At the same time, the past two years have seen more exits through initial public offerings (IPOs) and trade sales than any other two-year period. Eyepopping valuations totaling over $100 million have been obtained for several firms with preclinical stage technology. What were the cutting-edge biotech ventures that raised venture funding during this bumper year?

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Aaron Bouchie

  • Laura Defrancesco

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free